Limitations of Drugs of Abuse Testing

Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction

Volumn , Issue , 2013, Pages 213-232

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902052099     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415783-5.00014-1     Document Type: Chapter

References (96)

1. 2010 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, Rockville, MD. Available at: . http://www.oas.samhsa.gov/nhsda.htm.
2. Montoya I.D., Elwood W.N. Fostering a drug free workplace. Health Care Superv 1995, 14:1-3.
3. Carpenter C.S. Workplace drug testing and worker drug use. Health Serv Res 2007, 42L:795-810.
4. Jaffee W.B., Truccp E., Teter C., Levy S., et al. Focus on alcohol and drug abuse: ensuring validity in urine drug testing. Psychiatr Serv 2008, 59:140-142.
5. Jolley M.E., Stroupe S.D., Schwenzer K.S., et al. Fluorescence polarization immunoassay III: an automated system for therapeutic drug determination. Clin Chem 1981, 27:1575-1579.
6. Urine testing for drugs of abuse 1986, National Institute of Drug Abuse. Department of Health and Human Services, Rockville, MD, [NIDA research monograph 73]. R.L. Hawks, C.N. Chian (Eds.).
7. Jeon S.I., Yang X., Andrade J.D. Modeling of homogeneous cloned enzyme donor immunoassay. Anal Biochem 2004, 333:136-147.
8. Datta P., Dasgupta A. A new turbidimetric digoxin immunoassay on the ADVIA 1650 Analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit 2003, 25:478-482.
9. Dai J.L., Sokoll L.J., Chan D.W. Automated chemiluminescent immunoassay analyzers. J Clin Ligand Assay 1998, 21:377-385.
10. Montagne P., Varcin P., Cuilliere M.L., Duheille J. Microparticle-enhanced nephelometric immunoassay with microsphere-antigen conjugate. Bioconjugate Chem 1992, 3:187-193.
11. Fraser A.D., Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003, 25:723-727.
12. Soldin S.J., Morales A.J., D'Angelo L.J., Bogema S.C., Hicks J.C. The importance of lowering the cut-off concentrations of urine screening and confirmatory tests for benzoylecgonine/cocaine [Abstract]. Clin Chem 1991, 37:993.
13. Luzzi V.I., Saunders A.N., Koenig J.W., Turk J., et al. Analytical performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem 2004, 50:717-722.
14. Paul B., Past M.R. Confirmation methods in drug testing: an overview. Critical issues in alcohol and drugs of abuse testing 2009, 125-161. AACC Press, Washington, DC. A. Dasgupta (Ed.).
15. Maralikova B., Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 811:21-30.
16. Eichhorst J.C., Etter M.L., Rousseaux N., Lehotay D.C. Drugs of abuse testing by tandem mass spectrometry: a rapid simple method to replace immunoassay. Clin Biochem 2009, 42:1531-1542.
17. Kunsman G.W., Levine B., Kuhlman J.J., Jones R.L., et al. MDA-MDMA concentrations in urine specimens. J Anal Toxicol 1996, 20:517-521.
18. Stout P.R., Klette K.L., Wiegand R. Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in human urine. J Anal Toxicol 2003, 27:265-269.
19. Huang M.K., Dai Y.S., Lee C.H., Liu C., et al. Performance characteristics of DRI, CEDIA and REMEDi system for preliminary tests for amphetamines and opiates in urine. J Anal Toxicol 2006, 30:61-64.
20. Poklis A., Fitzgerald R.L., Hall K.V., Saddy J.J. EMIT-d.a.u monoclonal amphetamine/methamphetamine assay II: detection of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA). Forensic Sci Int 1993, 59:63-70.
21. Lin D.L., Liu H.C., Tin H.L. Recent paramethoxymethamphetamine (PMMA) deaths in Taiwan. J Anal Toxicol 2007, 31:109-113.
22. Kerrigan S., Mellon M.B., Banuelos S., Arndt C. Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamine. J Anal Toxicol 2011, 25:444-451.
23. Apollonio L.G., Whittall I.R., Pianca D.J., Kyd J.M., et al. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamines and methamphetamines. J Anal Toxicol 2007, 31:208-213.
24. Kerrigan S., Banuelos S., Perrella L., Hardy B. Simultaneous detection of ten psychedelic phenethylamine in urine by gas chromatography-mass spectrometry. J Anal Toxicol 2011, 35:459-469.
25. Ewald A.H., Fritschi G., Bork W.R., Maurer H.H. Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-diemthoxy-4-bromo-methamaphetamine (MDOB): studies of their metabolite and toxicological detection in rat urine using gas chromatography/mass spectrometric techniques. J Mass Spectrom 2006, 41:487-498.
26. Takahashi M., Nagashima M., Suzuki J., Seto T., et al. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrometry detector and gas chromatography-mass spectrometry. Talanta 2009, 77:1245-1272.
27. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetmaine) overdose. Forensic Sci Int 2005, 153:85-91.
28. Stout P.R., Klette K.L., Horn C.K. Evaluation of ephedrine, pseudoephedrine, and phenylpropanolamine concentrations in human urine specimens and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Foresnic Sci 2004, 49:160-164.
29. Poklis A., Jortani W.S.A., Brown C.S., Crooks C.R. Response of the EMIT II amphetamine/methamphetamine assay to specimens collected following use of Vicks inhalers. J Anal Toxicol 1993, 17:284-286.
30. Dietzen D.J., Ecos K., Friedman D., Beason S. Positive predictive values of abused drug immunoassays on the Beckman SYNCHRON in a Veteran population. J Anal Toxicol 2001, 25:174-178.
31. Logan B.K., Costantino A.G., Rieders E.F., Sanders D. Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite) and the hallucinogen trifluoromethylphenylpiperazine cross-react with EMITII ecstasy immunoassay in urine. J Anal Toxicol 2010, 34:587-589.
32. Baron J.M., Griggs D.A., Nixon A.L., Long W.H., et al. The trazodone metabolite meta-chlorophenylpiperazine can cause false positive urine amphetamine immunoassay result. J Anal Toxicol 2011, 35:364-368.
33. Yee L.M., Wu D. False positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol 2011, 117(2 Pt 2):503-506.
34. Casey E.R., Scott M.G., Tang S., Mullins M.E. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol 2011, 7:105-108.
35. Vidal C., Skripuletz T. Bupropion interference with immunoassays for amphetamines and LSD. Ther Drug Monit 2007, 29:373-375.
36. Merigian K.S., Beowning R.G. Desipramine and amantadine causing false positive urine test for amphetamine. Ann Emerg Med 1993, 22:1927-1928.
37. Kraemer T., Wenning R., Maurer H.H. The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassays (FPIA) studies on the toxicological analysis of urine by FPIA and GC-MS. J Anal Toxicol 2001, 25:333-338.
38. Vorce S.P., Holler J.M., Cawrse B.M., Magluilo J. Dimethylamine: a drug causing positive immunoassay results for amphetamines. J Anal Toxicol 2011, 35:183-187.
39. Armbruster D.A., Schwarzhoff R.H., Hubster E.C., Liserio M.K. Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay and fluorescence polarization immunoassay compared for drugs of abuse screening. Clin Chem 1993, 39:2137-2146.
40. Baker J.E., Jenkins A.J. Screening for cocaine metabolite fails to detect an intoxication. Am J Forensic Med Pathol 2008, 29:141-144.
41. Dasgupta A., Mahle C., McLemore J. Elimination of fluconazole interference in gas chromatography/mass spectrometric confirmation of benzoylecgonine, the major metabolite of cocaine using pentafluoropropionyl derivative. J Forensic Sci 1996, 41:511-513.
42. Mazor S.S., Mycyk M.B., Wills B.K., Brace L.D., et al. Coca tea consumption causes positive urine cocaine assay. Eur J Emerg Med 2006, 13:340-341.
43. Smith M.L., Hughes R.O., Levine B., Dickerson S., et al. Forensic drug testing for opiates: VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 1995, 19:18-26.
44. Abadie J.M., Allison K.H., Black D.A., Garbin J., et al. Can an immunoassay become a standard technique in detecting oxycodone and its metabolites?. J Anal Toxicol 2005, 29:825-829.
45. Gingras M., Laberge M.H., Lafebvre M. Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine. J Anal Toxicol 2010, 34:78-83.
46. Snyder M.L., Jarolim P., Melanson S.E. A new automated urine fentanyl immunoassay: technical performance and clinical utility for monitoring fentanyl compliance. Clin Chim Acta 2011, 412:946-951.
47. Armstrong E.J., Jenkins A.J., Sebrosky G.F., Balraj E.K. An unusual fatality in a child due to oxycodone. Am J Forensic Med Pathol 2004, 25:338-341.
48. Holler J.M., Bosy T.Z., Klette K.L., Wiegand R., et al. Comparison of the microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for detection of heroin use in forensic urine samples. J Anal Toxicol 2004, 28:489-493.
49. Straseski J.A., Stolbach A., Clarke W. Opiate positive immunoassay screen in a pediatric patient. Clin Chem 2010, 56:1220-1225.
50. Hull M.J., Bierer M.F., Griggs D.A., Long W.H., et al. Urinary buprenorphine concentration in patients treated with Suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J Anal Toxicol 2008, 32:516-521.
51. Baden L.R., Horowitz G., Jacoby H., Eliopoulos G.M. Quinolones and false positive urine screening for opiates by immunoassay technology. JAMA 2001, 286:3115-3119.
52. Straley C.M., Cecil E.J., Herriman M.P. Gatifloxacin interfere with opiate urine drug screen. Pharmacotherapy 2006, 26:435-439.
53. De Paula M., Saiz L.C., Gonzalez-Revalderia J., Pascual T., et al. Rifampicin causes false positive immunoassay results for opiates. Clin Chem Lab Med 1998, 36:241-243.
54. Widschwendter C.G., Zernig G., Hofer A. Quetiapine cross-reactivity with urine methadone immunoassays [Letter to the Editor]. Am J Psychiatry 2007, 164:172.
55. Rogers S.C., Pruitt C.W., Crouch D.J., Caravati E.M. Rapid urine drug screens: diphenhydramine and methadone cross-reactivity. Pediatr Emerg Care 2010, 26:665-666.
56. Hausmann E., Kohl B., von Boehmer H., Wellhoner H.H. False positive EMIT indication for opiates and methadone in doxylamine intoxication. J Clin Chem Clin Biochem 1983, 21:599-600.
57. Frederick D.L., Green J., Fowler M.W. Comparison of six cannabinoid metabolite assays. J Anal Toxicol 1985, 9:116-120.
58. Rohrich J., Schimmel I., Zorntlein S., Becker J., et al. Concentrations of delta-9-tetrahydrocannabinol and 11-nor 9-carboxytetrahydrocannabinol in blood and urine after passive exposure to cannabis smoke in a coffee shop. J Anal Toxicol 2010, 34:196-203.
59. Zawilska J.B. "Legal highs"-New players in the old drama. Curr Drug Abuse Rev 2011, 4:122-130.
60. Vardakou I., Pistos C., Spiliopoulou C.H. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157-162.
61. Boucher A., Vilette P., Crassard N., Bernard N., et al. Urinary toxicological screening: analytical interference between niflumic acid and cannabis. Arch Pediatr 2009, 16:1457-1460. [In French].
62. Oosthuizen N.M., Laurens J.B. Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol. Ann Clin Biochem 2011, 49:194-196.
63. Marchei E., Pellegrini M., Pichini S., Martin I., et al. Are false positive phencyclidine immunoassay instant-view multi test results caused by overdose concentrations of ibuprofen, metamizol and dextromethorphan?. Ther Drug Monit 2007, 29:671-673.
64. Long C., Crifasi J., Maginn D. Interference of thioridazine (Mellaril) in identification of phencyclidine. Clin Chem 1996, 42:1885-1886. [Letter to the Editor].
65. Bond G.R., Steele P.E., Uges D.R. Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine. J Toxicol Clin Toxicol 2003, 41:999-1002.
66. West R., Pesce A., West C., Crews B., et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in patient management. Pain Physician 2010, 13:71-78.
67. Forsman M., Nystrom I., Roman M., Berglund L., et al. Urinary detection times and excretion patterns of flunitrazepam and its metabolites after a single oral dose. J Anal Toxicol 2009, 33:491-501.
68. Kurisaki E., Hayashida M., Nihira M., Ohno Y., et al. Diagnosis performance of Triage for benzodiazepines: urine analysis of the dose of therapeutic cases. J Anal Toxicol 2005, 29:539-543.
69. Augsburger M., Rivier L., Mangin P. Comparison of different immunoassays and GC-MS screening of benzodiazepines in urine. J Pharm Biomed Anal 1998, 18:681-687.
70. Wenk R.E. False negative urine immunoassay after lorazepam overdose. Arch Pathol Lab Med 2006, 130:1600-1601. [Letter to the Editor].
71. Lum G., Mushlin B., Farney L. False positive rates for the qualitative analysis of urine benzodiazepines and metabolites with the reformulated Abbott Multigent reagents. Clin Chem 2008, 54:220-221. [Letter to the Editor].
72. Fraser A.D., Howell P. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. J Anal Toxicol 1998, 22:50-54.
73. McNally A.J., Pilcher I., Wu R., Salamone S.J., et al. Evaluation of the online immunoassay for propoxyphene: comparison to EMIT II and GC-MS. J Anal Toxicol 1996, 20:537-540.
74. Schneider S., Wennig R. Interference of diphenhydramine with the EMIT II immunoassay for propoxyphene. J Anal Toxicol 1999, 23:637-638.
75. Brenner C., Hui R., Passarelli J., Wu R., et al. Comparison of methaqualone excretion patterns using Abuscreen ONLINE and EMIT II immunoassay and GC/MS. Forensic Sci Int 1996, 79:31-41.
76. Joseph R., Dickerson S., Willis R., Frankenfield D., et al. Interference by nonsteroidal antiinflammatory drugs in EMIT and TDx assays for drugs of abuse. J Anal Toxicol 1995, 19:1-7.
77. Rollins D.E., Jennison T.A., Jones G. Investigation of interference by non-steroidal antiinflammatory drugs in urine tests for abused drugs. Clin Chem 1990, 36:602-606.
78. Mikkelsen S.L., Ash O. Adulterants causing false negative in illicit drug test. Clin Chem 1988, 34:2333-2336.
79. Warner A. Interference of household chemicals in immunoassay methods for drugs of abuse. Clin Chem 1989, 35:648-651.
80. Wu A., Bristol B., Sexton K., Cassella-McLane G., Holtman V., Hill D.W. Adulteration of urine by Urine Luck. Clin Chem 1999, 45:1051-1057.
81. George S., Braithwaite R.A. The effect of glutaraldehyde adulteration of urine specimens on Syva EMIT II drugs of abuse assay. J Anal Toxicol 1996, 20:195-196.
82. ElSohly M.A., Feng S., Kopycki W.J., Murphy T.P., Jones A.B., Davis A., et al. A procedure to overcome interference's caused by adulterant "Klear" in the GC-MS analysis of 11-nor-D9-THC-9-COOH. J Anal Toxicol 1997, 20:240-242.
83. Urry F., Komaromy-Hiller G., Staley B., Crockett D., Kushnir M., Nelson G., et al. Nitrite adulteration of workplace drug testing specimens: sources and associated concentrations of nitrite and distinction between natural sources and adulteration. J Anal Toxicol 1998, 22:89-95.
84. Dasgupta A., Wahed A., Wells A. Rapid spot tests for detecting adulterants in urine specimens submitted for drug testing. Am J Clin Pathol 2002, 117:325-329.
85. Dasgupta A., Chughtai O., Hannah C., Davis B., Wells A. Comparison of spot test and AdultaCheck 6 and Intect 7 urine test strips for detecting the presence of adulterants in urine specimens. Clin Chim Acta 2004, 348:19-25.
86. Bush D.M. The US mandatory guidelines for federal workplace drug testing programs: current status and future considerations. Forensic Sci Int 2008, 174:111-119.
87. Melanson S.E., Baskin L., Magnani B., Kwong T.C., et al. Interpretation and utility of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med 2010, 134:735-739.
88. Wiegand R.F., Klette K.L., Stout P.R., Gehlhausen J.M. Comparison of EMIT II, CEDIA and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples. J Anal Toxicol 2002, 26:519-523.
89. Gagajewski A., David G.K., Poch G.K., Anderson C.J., et al. False positive lysergic acid diethylamide immunoassay screen associated with fentanyl medication. Clin Chem 2002, 48:205-206. [Letter to the Editor].
90. Elian A.A. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. Forensic Sci Int 2001, 122:43-47.
91. Carstairs S.D., Cantrill F.L. Peyote and mescaline exposures: a 12 year review of a statewide poison center database. Clin Toxicol 2010, 48:350-353.
92. Reynolds P.C., Jindrich E.J. A mescaline associated fatality. J Anal Toxicol 1985, 9:183-184.
93. Tiscione N.B., Miller M.I. Psilocin identified in a DUID investigation. J Anal Toxicol 2006, 30:342-345.
94. McClintock R.L., Watts D.J., Melanson S. Unrecognized magic mushroom abuse in a 28 year old man. Am J Emerg Med 2008, 26(972):e3-e4.
95. Brahm N.C., Yeager L.L., Fox M.D., Farmer K.C., et al. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm 2010, 67:1344-1350.
96. Tenore P.L. Advanced urine toxicology testing. J Addictive Dis 2010, 29:436-448.